Sunshine Biopharma, Inc.

What they do

The company operates through two wholly owned Canadian subsidiaries. Nora Pharma holds rights to import, market, sell and distribute generic prescription drugs in Canada, filing Abbreviated New Drug Submissions with Health Canada and selling under its own label or partner labels. Sunshine Biopharma Canada develops and sells OTC supplements. Separately, the company is developing two proprietary candidates: K1.1 mRNA, an LNP-encapsulated mRNA targeting liver cancer, and SBFM-PL4, a protease inhibitor for SARS Coronavirus infections.

Revenue drivers

• Generic prescription drugs (Nora Pharma) — The dominant revenue source; the 10-K lists 71 generic drugs on the market in Canada and the 10-Q lists 60, spanning oncology, cardiovascular, CNS, antibacterial and other therapeutic areas, sold under Nora Pharma or partner labels.
• OTC supplements (Sunshine Biopharma Canada) — A Canadian subsidiary that develops and sells over-the-counter supplement products, described in the filings with no separate revenue figure disclosed.
• New generic launches — Revenue growth is tied to adding approved generic products; the company launched nine new generic prescription drugs in 2025 and planned 12 additional launches for the remainder of 2026.
• Proprietary drug programs (K1.1 mRNA, SBFM-PL4) — Pre-revenue development programs in liver cancer and SARS Coronavirus; no product revenue is reported from these candidates.

Recent performance

Fiscal 2025 revenue was $36.3 million, up 4.1% from $34.9 million in 2024. Gross profit rose to $12.26 million from $10.67 million, while G&A expenses increased to $18.48 million from $16.48 million, driven partly by a $1.75 million non-cash impairment charge on intangible assets. Net loss was $5.98 million in 2025 versus $5.13 million in 2024. Quarterly revenue was $9.4 million in Q3 2025, $8.6 million in Q4 2025, $8.1 million in Q1 2026 and $9.3 million in Q2 2026. Operating cash flow improved to negative $5.3 million in 2025 from negative $12.5 million in 2024.

Strategy

Management says it is focused on expanding the generic drug portfolio in Canada and advancing the two proprietary development programs. The company raised $2.46 million in gross proceeds through a registered direct offering to support expansion of sales operations. In January 2026 it implemented cost-reduction initiatives aimed at lowering G&A expenses, expected to reduce expenses by approximately $2 million to $3 million in 2026, though it states no assurance these reductions will be fully realized. It has also been active on the corporate side, filing multiple 8-Ks since April 2026 covering material agreements and an officer or director change. CEO Dr. Steve Slilaty said the company remains committed to reaching profitability in the near future.

Risks

• No profitability to date — The company reported an accumulated deficit of $75,015,126 as of December 31, 2025, with net losses of $5,975,352 in 2025 and $5,134,116 in 2024, and states it may never achieve profitability.
• Generic pharmaceutical margin and pricing pressure — Revenue depends on generic drugs sold in Canada, which the company describes as generally significantly less profitable than innovative medicines, with pricing shaped by the pan-Canadian Pharmaceutical Alliance.
• Supply chain and macroeconomic disruption — The company cites ongoing supply chain issues, rising inflation, tariff escalations, geopolitical conflict and regulatory or labor actions as risks that could cause supply discontinuities and delay its ability to meet demand.
• Early-stage proprietary programs — K1.1 mRNA and SBFM-PL4 remain development-stage candidates with no reported product revenue, and the company also recorded a $1.75 million impairment charge on intangible assets in 2025.

Outlook

Management expects further growth in 2026 from expanding the generic drug portfolio, with 12 additional launches planned for the remainder of the year after nine launches in 2025. It expects the January 2026 cost-reduction initiatives to lower expenses by approximately $2 million to $3 million in 2026, though it cautions the reductions may not be fully realized. The company says it remains committed to reaching profitability in the near future and continues to advance its K1.1 mRNA and PLpro antiviral programs.